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Abstract The mitochondrial respiratory chain is a powerful
source of reactive oxygen species, considered as the pathogenic
agent of many diseases and of aging. We have investigated the
role of Complex I in superoxide radical production in bovine
heart submitochondrial particles and found, by combined use of
specific inhibitors of Complex I and by Coenzyme Q (CoQ)
extraction from the particles, that the one-electron donor in the
Complex to oxygen is a redox center located prior to the binding
sites of three different types of CoQ antagonists, to be identified
with a Fe^S cluster, most probably N2 on the basis of several
known properties of this cluster. Short chain CoQ analogs
enhance superoxide formation, presumably by mediating electron
transfer from N2 to oxygen. The clinically used CoQ analog,
idebenone, is particularly effective in promoting superoxide
formation. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Reactive oxygen species (ROS) is a cumulative designation
for the products of partial reduction of molecular oxygen and
comprehend both free radicals and neutral molecular species.
There are several reactions in cells that are able to give rise to
superoxide anion radical and/or to hydrogen peroxide; the
latter can react with a reduced metal ion (such as Fe2 or
Cu) and give rise to the most aggressive hydroxyl radical.
There is almost no area of human pathology where oxida-
tive stress has not been implicated since ROS are considered
as the main pathogenic agents of most diseases [1]. Moreover,
it is currently believed that ROS are involved in the progres-
sive deterioration of cell structures accompanying ageing [2].
Within a cell, mitochondria largely contribute to the pro-
duction of ROS via the respiratory chain [3]. The relevance of
mitochondrial production of ROS within a cell is indirectly
revealed by the results of de¢ciency of mitochondrial antioxi-
dant enzymes. The e¡ect of knock-out of the superoxide dis-
mutase (SOD)-2 gene for mitochondrial SOD in transgenic
mice is dramatic, with inability to survive for more than
2 weeks after birth and development of a series of biochemical
defects ascribed to oxidative stress [4]. This means that the
enzyme function is vital in the normal cell for preventing the
toxic e¡ect of superoxide radical generated in the mitochon-
dria. Similarly, the lack of mitochondrial glutathione peroxi-
dase is deleterious in that the accumulation of hydrogen per-
oxide in the presence of reduced metal ions leads to the
extremely toxic hydroxyl radical [5].
It has long been understood that the major sites of super-
oxide formation in the respiratory chain are within respiratory
complexes I and III [6]. Early experiments proved the involve-
ment of Complex I (NADH Coenzyme Q (CoQ) reductase) in
ROS production [7]; addition of either NADH at low con-
centration or of NADPH, which feeds the electrons at de-
creased rate into the Complex, led to copious ROS production
detected by lipid peroxidation; on the other hand, addition of
NADH at high concentration, but in presence of rotenone,
also induced peroxidation. In another study [8] water-soluble
CoQ homologs used as electron acceptors from isolated Com-
plex I-stimulated H2O2 production in the order
CoQ1sCoQ0sCoQ2, whereas CoQ6 and CoQ10 were inac-
tive; the rate of H2O2 production was partly inhibited by
rotenone, indicating that water-soluble quinones may react
with oxygen when reduced at sites both prior and subsequent
to the rotenone block. There is evidence that the one-electron
donor to oxygen in Complex I is a non-physiological quinone
reduction site di¡erent from the physiological site [9,10] ; the
former, hydrophilic site reduces several quinones to the cor-
responding semiquinone forms, which are unstable and can
reduce oxygen to superoxide. This mechanism is shared by
several quinones, including such drugs as anthracyclines [11]
and the clinically employed CoQ analog, idebenone [12]. In
view of the experiments of Takeshige et al. [7], the hydro-
philic, rotenone-insensitive site can apparently reduce oxygen
to superoxide in absence of intermediate acceptors. A series of
recent studies by Barja and coworkers con¢rmed that Com-
plex I is a major source of superoxide production in several
types of mitochondria [13] and localized the oxygen reducing
site between the ferricyanide reducing site and the rotenone
block [14].
The presence of antioxidant enzymes in the mitochondrial
matrix [4,5,15] makes it di⁄cult to localize the site(s) of ROS
production in intact mitochondria. Although the ¢rst product
of oxygen reduction by the respiratory chain is certainly
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superoxide, this radical has a short life and is rapidly con-
verted into hydrogen peroxide by mitochondrial SOD or by
spontaneous disproportionation, or can attack other mole-
cules, such as lipids, before being able to escape the mito-
chondrion. For this reason identi¢cation of the site(s) of
superoxide production can best be achieved in submitochon-
drial particles (SMP) which are devoid of matrix (antioxidant)
enzymes and do expose the respiratory enzymes to the exter-
nal medium.
In this study we provide further evidence pertaining to the
site of superoxide production in Complex I in bovine heart
SMP by exploiting a series of inhibitors acting at di¡erent
sites in the route of electrons and by studying the behavior
of CoQ-depleted and -reconstituted mitochondrial particles.
In particular we have used p-hydroxy-mercuribenzoate, which
inhibits at the level of iron^sulfur clusters of the Complex [16],
and three classes of quinone antagonists according to the
nomenclature of Degli Esposti [17], acting at three di¡erent
hydrophobic sites in the Complex. The results of this inves-
tigation provide evidence that the source of one-electron re-
duction of oxygen in the Complex is not endogenous bound
ubisemiquinone but is an iron^sulfur cluster, presumably N2
in view of its physico-chemical properties and its ability to
interact with endogenous ubiquinone [18].
2. Materials and methods
Most chemicals were obtained from Sigma Co., St. Louis, MO,
USA. Idebenone was a gift of Dr. M. Degli Esposti, University of
Glasgow, UK. Rolliniastatin-1 and -2 were gifts of Dr E. Estornell of
the University of Valencia, Spain. Mucidin (strobilurin A) was a gift
from Dr. J. Subik of the University of Bratislava, Slovakia.
SMP were prepared from bovine heart mitochondria as described
elsewhere [19]. CoQ-depleted SMP were prepared by pentane extrac-
tion of lyophilized particles according to Szarkowska [20], and recon-
stitution with CoQ10 was achieved by adding the quinone in pentane
to the dried sample as described by Norling et al. [21] The CoQ
content of di¡erent types of particles was determined by high per-
formance liquid chromatography (HPLC) as described elsewhere [22].
NADH oxidase, NADH CoQ reductase (using decyl-ubiquinone
(DB) as acceptor), and ubiquinol cytochrome c reductase activities
were assayed as described previously [23]. All inhibitors used were
at least 95% e¡ective at the concentrations used, except p-hydroxy-
mercuribenzoate and myxothiazol that were employed at concentra-
tions giving ca. 90% and 82% inhibition respectively.
Superoxide production was assayed by exploiting the oxidation of
epinephrine to adrenochrome by the superoxide radical [24] in a Sig-
ma-Biochem ZWS2 double-wavelength spectrophotometer thermo-
stated at 25‡C, at 4853575 nm, using an extinction coe⁄cient of
2.96 mM31 cm31. A standard curve was obtained by using a xan-
thine^xanthine oxidase system for the generation of superoxide. The
system contained 10 mM Tris^HCl, 50 mM KCl and 1 mM ethyl-
enediaminetetraacetate (EDTA), pH 7.8, 0.5 WM catalase, 1 mM epi-
nephrine and 0.5 mg SMP, in presence of di¡erent inhibitors as de-
scribed in the text; the reaction was started by addition of 125 WM
NADH (occasionally by 12.5 WM DBH2 for estimation of superoxide
production by Complex III); after 15 min recording, eventual addi-
tion of Complex I acceptors (DB, CoQ1, CoQ2) was performed and
the trace was recorded for 5 additional min. At the end, SOD (Sigma,
from bovine liver), 13 Wg, was added and the trace was recorded for
10 min The rate was usually inhibited by SOD by 90% or more. The
results are expressed as SOD-sensitive activity by subtracting the ac-
tivity in presence of SOD, unless otherwise speci¢ed.
3. Results
In order to functionally isolate superoxide production by
Complex I only, its formation by Complex III was prevented
using mucidin, an inhibitor of center o. We avoided to use
antimycin A, since this center i inhibitor is known to enhance
superoxide formation [25], and myxothiazol, another center o
inhibitor that however also inhibits Complex I [26]. The e¡ect
of antimycin A and mucidin on superoxide production by
Complex III is shown in Table 1: as expected, antimycin A
strongly stimulated superoxide production, however mucidin
had no e¡ect. For this reason, all subsequent experiments
were performed in presence of 1.8 WM mucidin.
At di¡erence with the ¢ndings of Barja [14] we observed
very low superoxide production after NADH addition to non-
inhibited SMP. Addition of NADH to mucidin-inhibited SMP
enhanced superoxide formation 4-fold; the mucidin-stimu-
lated activity was inhibited by p-hydroxy-mercuribenzoate
and was further enhanced to similar extents (about 3-fold)
by Complex I inhibitors belonging to all three classes of qui-
none antagonists and by combinations thereof (Fig. 1). Addi-
tion of short chain analogs and homologs of CoQ (CoQ1,
CoQ2, DB) enhanced superoxide formation of non-inhibited
Complex I (in presence of mucidin) and this enhancement was
further stimulated by the hydrophobic Complex I inhibitors
(Fig. 2): the three acceptors were e¡ective in the order
CoQ1sDBsCoQ2. The Complex I activity in SMP, mea-
sured as NADH-DB reductase under the same conditions,
was 299 þ 47 nmol (i.e. 598 electron equivalents) min31 (mg
protein)31 ; thus, the electrons escaping to oxygen in presence
of DB were 0.4% in absence of Complex I inhibitors and 1.4%
in presence of hydrophobic inhibitors.
Fig. 1. Superoxide radical production by Complex I in bovine SMP
in the presence of 125 WM NADH and no Complex I acceptor; mu-
cidin (MUC) (1.8 WM) was added to inhibit Complex III. The con-
centrations of the other inhibitors on top of mucidin were: p-hy-
droxy-mercuribenzoate (pHMB) (Fe^S cluster inhibitor), 59 WM;
rolliniastatin-2 (ROL) (Center A inhibitor), 0.2 nmol mg31 protein;
rotenone (ROT) (Center B inhibitor), 0.2 nmol mg31 protein; cap-
saicin (CAP) (Center C inhibitor), 4 Wmol mg31 protein; myxothia-
zol (MYX) (Center C inhibitor), 170 nmol mg31 protein. Inhibitor
classes are according to the nomenclature of Degli Esposti [17] (cf.
Fig. 3). The lower e¡ect of myxothiazol with respect to capsaicin
may be related to its lower extent of Complex I inhibition at the
concentration used (82% vs. 99%).
Table 1
E¡ect of Complex III inhibitors on superoxide production in bovine
heart SMP
Inhibitor Activity 3SOD Activity +SOD
None 0.27 þ 0.16 0.01 þ 0.02
Mucidin (1.8 WM) 0.23 þ 0.03 0.04 þ 0.06
Antimycin A (0.2 mg ml31) 2.41 þ 0.31 0.21 þ 0.17
Superoxide production was assayed as described in Section 2. The
activity was determined with 12.5 WM DBH2 as a substrate. Activity
is expressed as nmol min31 (mg protein)31.
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The behavior of idebenone was particularly striking, as it
stimulated superoxide production in mucidin-inhibited SMP
almost 20-fold; idebenone is a type A inhibitor but is also an
electron acceptor from the Complex [17].
The e¡ect of CoQ extraction and reconstitution from
lyophilized mitochondria is shown in Table 2: apart from
the low extent of rotenone stimulation of superoxide produc-
tion in all particles that had undergone lyophilization, the
superoxide production in mucidin-inhibited particles was not
changed by extraction of the endogenous CoQ10. The stimu-
lation by DB was about the same as in non-extracted SMP.
The extent of extraction of endogenous CoQ was checked by
HPLC: the extracted particles were found to contain a resid-
ual amount of 83 pmol CoQ (mg protein)31, in accordance
with previous results [22], vs. an amount of 3.03 nmol mg31 in
the parent lyophilized particles and an excess of 15.7 nmol
mg31 in the reconstituted ones.
4. Discussion
Bovine heart SMP respiring with NADH under non-inhib-
ited conditions produce low amounts of superoxide radical at
25‡C (0.27 þ 0.16 nmol min31 (mg protein)31), nevertheless
comparable with the results of Herrero and Barja [14] in
cow SMP (2.5 þ 0.3 nmol min31 mg31, however at 37‡C). In
order to functionally isolate Complex I from the downstream
segments of the respiratory chain in membranes containing
the entire respiratory chain, one has to add a respiratory in-
hibitor acting at the level of Complex III. This manipulation
has the further advantage of maintaining the respiratory chain
components upstream of Complex III more reduced, thus
favoring interaction with oxygen of the auto-oxidizable com-
ponents (cf. [27]). It is known that addition of antimycin A to
mitochondria respiring on either NAD-linked substrates or
succinate enhances ROS production at the level of Complex
III [25,28]: this inhibitor is therefore not suitable for the pur-
pose. According to the Q-cycle mechanism, center o inhibitors
should inhibit superoxide production by inhibiting semiqui-
none formation [29]. However myxothiazol, in absence of
antimycin, may induce ROS production [30] ; moreover myx-
othiazol is also an inhibitor of Complex I [26], therefore we
have used it in connection with our survey of Complex I
inhibitors. We have found that mucidin (or strobilurin A), a
center o inhibitor [31], does not stimulate superoxide genera-
tion by Complex III in SMP supplemented with ubiquinol
(Table 1). We have therefore used mucidin in most experi-
ments in order to functionally isolate Complex I.
Addition of NADH to mucidin-inhibited SMP results in a
4-fold enhancement of superoxide production with respect to
non-inhibited particles: this is expected, since these conditions
are bound to keep Complex I in a more reduced state, thus
favoring interaction of one or more redox centers with oxygen
[27]. Subsequent addition of rotenone and other inhibitors,
belonging to all three classes of antagonists of the ubiqui-
none-binding sites [17], further enhances superoxide formation
by about 3-fold. Thus the enhancing e¡ect of rotenone (and
the other hydrophobic inhibitors) on superoxide production
over that of non-inhibited SMP is more than 10-fold, com-
pared with a less than 2-fold e¡ect found by Herrero and
Barja [14]; this striking di¡erence might be explained by a
higher superoxide production by Complex III in absence of
Complex III inhibitors in the study by Herrero and Barja,
perhaps due to the di¡erent assay temperature (cf. above).
Addition of p-hydroxy-mercuribenzoate inhibits superoxide
generation, in agreement with the ¢nding of Herrero and
Barja [14], who also found inhibition by ethoxyformic anhy-
dride. While the former compound acts before the ferricya-
nide site, the latter acts after the same site [32], so that £avin
can be discarded as the free radical generator [14]. The en-
hancement of superoxide generation by the quinone antago-
nists belonging to all three classes of Degli Esposti’s classi¢-
cation [17] and by a combination thereof demonstrates that
the free radical generator is located before the quinone-bind-
ing sites. It is known that rotenone quenches the semiquinone
signal of CoQ bound to Complex I [33], and it is extremely
likely that a combination of inhibitors of the three classes
prevents formation of ubisemiquinone, thus excluding its
being the direct electron donor to oxygen. The oxygen radical
generator is therefore presumably an iron^sulfur cluster, in
agreement with the conclusion of Herrero and Barja [14].
This assumption was directly demonstrated in this study by
the observation that CoQ depletion has no e¡ect on super-
oxide production in mucidin-inhibited SMP. To this purpose
it has to be noted that even a large excess of CoQ10, as in the
CoQ-reconstituted particles, has no e¡ect on superoxide pro-
duction by Complex I, although the short chain analog DB
added to the reconstituted particles enhances its generation to
similar extents as in the extracted particles (cf. Table 2).
Addition of the commonly used acceptors for Complex I
activity determination, such as CoQ1, CoQ2, and DB, in pres-
ence of NADH and mucidin, also enhances superoxide pro-
duction, both in SMP and in CoQ-depleted SMP. This obser-
vation means that all of these acceptors, besides acting at the
 
Fig. 2. Superoxide radical production by Complex I in the presence
of 125 WM NADH, 1.8 WM mucidin and 60 WM acceptor, either
DB; CoQ1, or CoQ2. Inhibitor concentrations were the same as in
the legend of Fig. 1. Idebenone (IDE) was 2 Wmol (mg protein)31.
Table 2
Superoxide production in SMP after pentane extraction (SMP 3Q)
and reconstitution with CoQ10 (SMP +Q) (cf. Section 2)
Particle Addition 3DB +DB
SMP 3Q ^ 0.57 þ 0.05 1.91 þ 0.51
SMP 3Q rotenone (2 nmol mg31) 0.73 þ 0.01 2.64 þ 0.93
SMP +Q ^ 0.60 þ 0.05 1.41 þ 0.03
SMP +Q rotenone (2 nmol mg31) 0.57 þ 0.05 2.87
The endogenous CoQ10 content was 83 pmol mg31 in the extracted
particles and 15.7 nmol mg31 in the reconstituted ones. Activities
were assayed in the presence of NADH and mucidin at the usual
concentrations and are expressed in nmol min31 (mg protein)31.
[DB] when added was 60 WM.
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‘physiological’ site for CoQ10 of the pool, also interact at a
site situated upstream with respect to the binding site of the
ubiquinone antagonists, becoming reduced to semiquinones,
which, in turn, reduce molecular oxygen to superoxide. This
redox cycle is facilitated by the partially hydrophilic nature of
these quinone acceptors.
The observation that short-chain quinone analogs enhance
superoxide formation can be a hint on the identi¢cation of the
redox center responsible for oxygen radical formation. It is
likely, in fact, that this center is naturally a direct electron
donor to protein-bound ubiquinone in the membrane, and
that the quinone analogs compete with this interaction from
within the water phase. Several reasons would point out that
such a center is the tetranuclear iron^sulfur cluster N2 (Fig.
3): it has the highest mid-point potential among the Fe^S
clusters of Complex I [34] and the redox potential is pH-de-
pendent [18,35] and it appears to be located at the interface
between the membrane subcomplex and the peripheral arm of
the Complex [36]; in view of the magnetic interactions be-
tween the spins of N2 and bound ubisemiquinone, N2 is be-
lieved to be the direct donor to bound CoQ in the Complex
[18,37] and it appears to be the immediate redox group prior
to the rotenone block [18].
The e¡ects of idebenone deserve a special comment. This
quinone analog shares the property of being a Complex I
inhibitor (of type A, according to Degli Esposti [17]) and an
electron acceptor. It was already shown [12] that idebenone is
strongly prone to stimulate oxygen radical generation by
Complex I; this study quantitatively de¢nes idebenone to be
by far the most e¡ective of the compounds tested in eliciting
superoxide formation. It is remarkable that idebenone has a
strong use in clinical experimentation [38] as a substitute of
CoQ10 in therapy of mitochondrial cytopathies and of neuro-
degenerative diseases [39]. The observation that idebenone
promotes oxidative stress on one hand may indicate that its
behavior is di¡erent in vivo, on the other may suggest caution
in its use as a drug.
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Fig. 3. A model of electron transfer in Complex I showing the site
of superoxide production proposed on the basis of the results of the
present study. The scheme follows the model of Degli Esposti [14]
and depicts Fe^S cluster N2 as the source of electrons to bound
ubiquinone (Center B) and to the ubiquinone molecule deriving
from the pool (Center A). The two derived semiquinones dismutate
so that Center B contains oxidized ubiquinone, while the reduced
ubiquinone (ubiquinol) moves to Center C where from it is released
to the pool. The e¡ect of di¡erent inhibitors and acceptors (see
text) is compatible with Fe^S cluster N2 as the source of one elec-
tron to oxygen or to exogenous quinones (in place of the endoge-
nous bound CoQ10), which, in turn, reduce oxygen to superoxide.
Idebenone behaves both as an acceptor and as a type A inhibitor.
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